Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).

Full DD Report for ADMS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADMS)

Morgan Stanley upgrades Teva and Bausch in premarket analyst action
Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 08:47
Healthcare and Tech top list of midday movers (11/02/2018)
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: November, 02 2018 12:47
Adamas Pharma down 22% after Q3 report, slow market penetration for Gocovri
Adamas Pharmaceuticals ( ADMS -21.9% ) slumps on nearly double normal volume in reaction to its Q3 results released after the close yesterday. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more...
Source: SeekingAlpha
Date: November, 02 2018 10:42
Adamas Pharmaceuticals' (ADMS) Greg Went on Q3 2018 Results - Earnings Call Transcript
Adamas Pharmaceuticals, Inc. (ADMS) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Ashleigh Barreto – Director-Investor Relations and Corporate Communications Greg Went – Chairman and Chief Executive Officer Alf Merriweather – Chief F...
Source: SeekingAlpha
Date: November, 01 2018 22:16
Adamas Pharma beats by $0.12, beats on revenue
Adamas Pharma (NASDAQ: ADMS ): Q3 GAAP EPS of -$1.22 beats by $0.12 . Revenue of $10.6M beats by $0.46M . Press Release More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 01 2018 16:04
Adamas Reports Third Quarter 2018 Financial Results
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical compan...
Source: GlobeNewswire
Date: November, 01 2018 16:01
Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp. (NASD...
Source: GlobeNewswire
Date: October, 16 2018 09:15
Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect, Affimed Down On Clinical Hold
Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths ...
Source: SeekingAlpha
Date: October, 09 2018 13:47
VistaGen: Expensive At 12x Its Book Value Per Share
After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote...
Source: SeekingAlpha
Date: October, 09 2018 09:38
Adamas Pharma's Gocovri shows long-term treatment effect in late-stage Parkinson's study
Final results from a two-year open-label Phase 3 clinical trial, EASE LID 2 , evaluating Adamas Pharmaceuticals' ( ADMS -3.1% ) GOCOVRI (amantadine) in patients with Parkinson's disease (PD) showed a sustained treatment effect. The data were presented at the International Congress of P...
Source: SeekingAlpha
Date: October, 08 2018 09:56

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1831.6932.6732.8530.03581,835
2018-05-1731.6932.6732.8530.03581,835
2017-02-0316.2416.3716.50316.00108,828
2017-02-0215.9216.0816.2915.68105,673
2017-02-0115.9715.9416.1815.68147,628

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0741,041109,78637.3827Short
2018-12-06209,785356,97958.7668Short
2018-12-0431,950104,10030.6916Cover
2018-12-0361,950130,23547.5679Short
2018-11-3034,33363,02754.4735Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMS.


About Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS)

Logo for Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADMS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: ADMS)

      Daily Technical Chart for (NASDAQ: ADMS)


      Stay tuned for daily updates and more on (NASDAQ: ADMS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADMS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADMS and does not buy, sell, or trade any shares of ADMS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/